CAMBRIDGE, Mass. and TOKYO, Japan, May 15, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) of investigational agent tivozanib in patients with advanced renal cell carcinoma (RCC) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, May 31 – June 4, 2013.
The schedule for tivozanib poster presentations at ASCO is as follows:
Date & Time: Monday, June 3, 2013 from 8:00 to 11:45 a.m. CT
Session: General Poster Session, Genitourinary Cancer Track
Title: Rates of Dose Adjustment in Patients Treated with Tivozanib Versus Sorafenib in the Phase III TIVO-1 Study
Abstract Number: 4564
Location: S Hall A2, Poster Board #30H
Presenter: Thomas E. Hutson, D.O., Pharm.D.
Date & Time: Tuesday, June 4, 2013 from 8:00 a.m. to 12:00 p.m. CT; discussion from 11:30 to 11:45 a.m. CT
Session: Poster Discussion Session, Genitourinary Cancer Track
Title: Tivozanib in Patients Treatment-Naive for Metastatic Renal Cell Carcinoma: A Subset Analysis of the Phase III TIVO-1 Study
Abstract Number: 4513
Location: E450b, Poster Board #2
Presenter: Piotr Tomczak, M.D.